MedTrace Logo

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

NCT06151249 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-11-30

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.

Conditions

Interventions

COMBINATION_PRODUCT

Meritup oral solution

chemotherapy + Meritup

Sponsors & Collaborators

  • Phytofound Biotech Co., Ltd.

    collaborator UNKNOWN

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • Ming-Hsin Yeh, MD, PhD · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-11-30
Completion
2025-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06151249 on ClinicalTrials.gov